 |
|
Many Questions, Few Answers for Testosterone Replacement Therapy
Brian Vastag
JAMA. 2003;289:971-972.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Washington—The Web site advertisement would pique the interest of just about any man. As an animated gas gauge needle drops, questions appear. "Fatigued?" asks the ad. "Depressed mood? Low sex drive? Could be your testosterone is running on empty!"
The ad is from Unimed Pharmaceuticals Inc, the Marietta, Ga, marketer of a testosterone gel whose sales quadrupled to $144 million worldwide in 2001.
Approved by the US Food and Drug Administration (FDA) for hypogonadism, or clinically low testosterone in otherwise healthy men, testosterone replacement products are arousing concern from researchers who question a lack of data on long-term safety. So much so, in fact, that the Institute of Medicine (IOM) has been called on to help design large-scale studies.
"There is a humbling chasm of ignorance about testosterone replacement therapy," Marc Blackman, MD, clinical director at the National Center for Complementary and Alternative Medicine, told the IOM . . . [Full Text of this Article]
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman and Vermeulen
Endocr. Rev. 2005;26:833-876.
ABSTRACT
| FULL TEXT
|
